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Yellow fever (YF) 17D vaccine virus, having a 60-year history of safe and effective use, is an ideal vector to deliver
heterologous genes from other medically important flaviviruses. A chimeric YF/Japanese encephalitis (JE) virus (ChimeriVax-
JE virus) was constructed by insertion of the premembrane and envelope (prME) genes of an attenuated human vaccine
strain (SA14–14-2) of Japanese encephalitis (JE) virus between core and nonstructural (NS) genes of a YF 17D infectious
clone. The virus grew to high titers in cell cultures and was not neurovirulent for 3- to 4-week-old mice at doses #6 log10
plaque forming units (pfu) inoculated by the intracerebral (IC) route. In contrast, commercial YF 17D vaccine was highly
neurovirulent for weanling mice by the same route. Mice inoculated subcutaneously with one dose of $103 pfu of
ChimeriVax-JE virus were solidly protected against intraperitoneal challenge with a virulent JE virus. Genetic stability of the
chimera was assessed by sequential passages in cell cultures or in mouse brain. All attenuating residues and the avirulent
phenotype were preserved after 18 passages in cell cultures or 6 passages in mouse brains. © 1999 Academic Pressh
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Japanese encephalitis (JE) is an acute viral infection of
he central nervous system occurring throughout Asia.
pproximately 3 billion people live in endemic regions,
nd JE virus has been recently isolated in previously
onaffected areas of Australia (WHO, 98). Fifty thousand
E cases are reported officially each year of which 10,000
ases are fatal, and a high proportion of survivors have
eurological and psychiatric sequelae.
JE virus is a positive-stranded RNA virus within the
laviviridae family. The virus is transmitted from infected
nimals, mainly domestic pigs to humans by culicine
osquitoes. The most effective disease control measure
s vaccination of humans living in or traveling to endemic
reas. Currently three vaccines are available: (1) mouse-
rain-derived, inactivated vaccine, (2) cell-culture-
erived, inactivated vaccine, and (3) cell-culture-derived,
ive attenuated vaccine. The mouse-brain vaccine is the
nly vaccine that is commercialized internationally. The
accine is only moderately effective (91%) (Hoke et al.,
988) and requires two primary doses, one booster at 1
ear, and subsequent boosters every 3 years. In adults,
he mouse-brain vaccine has been associated with a
1 To whom reprint requests should be addressed. Fax: (617) 494-
927. E-mail: fguirakh@oravax.com.
2 Present address: Hercules Research Center, 500 Hercules Road,
ilmington, DE 19808.363igh incidence (0.6%) of allergic reactions and recently
everal cases of severe disseminated encephalitis have
een attributed to the vaccine (WHO, 1998). Due to the
ethod of manufacture and the requirement for multiple
oses, the cost of this vaccine is relatively high. In
ontrast, a cell-culture-derived vaccine (SA14–14-2 used
n China) is less expensive, but it is not produced to
nternational standards and requires at least two doses
or full protection (Hennessey et al., 1996). Therefore an
deal JE vaccine would be produced in an internationally
cceptable cell substrate, be genetically stable, require a
ingle dose, and be safe and effective. A model flavivirus
accine having these properties is the live, attenuated
ellow fever (YF) 17D, which has a remarkable record of
afety and efficacy over 60 years, induces life-long im-
unity after a single dose, and is extremely inexpensive
o manufacture (Barrett, 1997, Monath, 1999).
Recently Chambers et al., (1999) reported construc-
ion of a chimeric virus based on the core and NS
enes of the YF 17D vaccine strain and prME genes of
he SA14–14-2 virus (the Chinese JE vaccine). The
himeric virus had the antigenic specificity of JE virus
neutralized by anti-JE specific antibodies but not by
nti-YF antibodies) and was attenuated in mice inoc-
lated by the IC route.
In this paper, we describe the immunogenicity, protec-
ive efficacy, and genetic stability (in vitro and in vivo) of
he chimeric virus.0042-6822/99 $30.00
Copyright © 1999 by Academic Press
All rights of reproduction in any form reserved.
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364 GUIRAKHOO ET AL.RESULTS
rowth of ChimeriVax-JE virus in cell cultures
In Vero cells, the ChimeriVax-JE virus reached .8 log10
fu/ml in 5 days, whereas in LLC-MK2 cells, it grew
lower and peaked (6 log10 pfu/ml) at ;6 days.
In diploid rhesus monkey (FRhL) and human (MRC-5)
ells, ChimeriVax-JE grew to a lower titer. In FRhL cells
noculated at m.o.i. of 0.01 or 0.1, the chimeric virus grew
o a peak titer of 6 log10 pfu/ml. On Day 3, virus titers at
.o.i. of 1 (5 log10 pfu/ml) were lower than those at 0.1 or
.01. The effect of m.o.i. on growth kinetics of the Chi-
eriVax-JE virus was also evaluated in MRC-5 cells by
sing a high titer preparation of the chimeric virus pre-
ared by one additional passage in Vero cells. The virus
iter peaked on Day 2 at both m.o.i.s tested (6.2 and 5.9
og10 pfu for m.o.i. of 2 and 0.2, respectively). In contrast
o FRhL cells, higher m.o.i. resulted in higher virus yield
n MRC-5 cells.
ucleotide sequence of the ChimeriVax-JE
Envelope protein genes. The sequence of the JE por-
ion of the chimeric YF/JE virus was determined by RT–
CR analysis of the viral RNA extracted from infected cell
onolayers. The deduced amino acid sequence of the
nvelope protein E gene of the ChimeriVax-JE virus was
ompared with the published sequences for attenuated
A14–14-2 substrains and virulent SA14 and Nakayama
iruses (Table 1). Six amino acid differences at positions
07, 138, 176, 279, 315, and 439 distinguish all the atten-
ated SA14–14-2 substrains from both virulent JE viruses,
A14 and Nakayama. Four additional mutations at 177,
27, 244, and 264 distinguish the ChimeriVax-JE virus
rom the Nakayama strain. Mutations at positions 177,
43, and 264 seem to be host cell dependent because
hey are only found in SA14–14-2 virus propagated in
rimary hamster kidney (PHK) cells (the envelope genes
f the ChimeriVax-JE are derived from the PHK passaged
irus) but not in SA14–14-2 virus propagated in primary
T
Comparison of the Amino Acid Differences in
JE SA14-14-2 Substrains and Wild
Virus E 107 E 138 E 176 E 177
E SA14-14-2 PDK* F K V T
E SA14-14-2 PHK† F K V A
F/JE SA14-14-2 F K V A
F/JE Nakayama L E I T
E Nakayama§ L E I T
E SA14/JAP† L E I T
E SA14/CDC* L E I T
E SA14/USA‡ L E I T
Note. ChimeriVax-JE (YF/JE SA14-14-2) is shown in boldface.
* Nitayaphan et al. (1990); † Aihara et al. (1991); ‡ Ni et al. (1995); § Mog kidney (PDK) cells or in the parental SA14 virus.
ecause the PDK passaged virus has wild-type amino
cids at these positions but is attenuated, the mutations
t residues 177 and 264 in ChimeriVax-JE are unlikely to
lay a significant role in attenuation.
Yellow fever virus genes. The complete nucleotide se-
uence of the ChimeriVax-JE virus was determined and
ompared with published sequences for other YF 17D
accine substrains that represent independent passage
ineages from the original 17D virus described by Theiler
nd Smith (1937) (Table 2). There are 13 nucleotide and
amino acid differences among three 17D vaccine sub-
trains shown in Table 2. Six nucleotide differences and
wo amino acid changes were found when sequences of
he ChimeriVax-JE virus was compared with the pub-
ished sequences for its parent strain 17D-204 ATCC.
hanges at position 5461, 5641, 8212, and 8581 are silent
nd do not result in amino acid substitutions. The
hange at position 4025 results in an amino acid substi-
ution from M to V in the NS2A protein, and the change in
osition 7319 results in an amino acid substitution from
to E in the NS4B protein.
ttenuation of ChimeriVax-JE in mice
Three experiments were performed to compare the
eurovirulence phenotype of the ChimeriVax-JE virus
ith that of the YF 17D vaccine in suckling and young
dult mice (Table 3). In Experiment 1, ChimeriVax-JE virus
r YF 17D vaccine (YF-Vax) were inoculated into groups
f 3- to 4-week-old outbred (ICR) mice at varying doses
rom 5 to 1 log10 pfu via the IC or the SC routes. None of
ice inoculated by the SC route with either vaccine died,
hereas all mice inoculated by the IC route with 17D
accine ($3.4 log10 pfu) succumbed within 7–10 days p.i.
ll mice inoculated with ChimeriVax-JE virus survived the
C infection and developed neutralizing antibodies
gainst JE virus (data not shown). This experiment dem-
nstrated that the ChimeriVax-JE is not neurovirulent for
-week-old mice, whereas 17D vaccine is neurovirulent
Protein of ChimeriVax-JE (YF/JE SA14-14-2),
JE Viruses SA14 and Nakayama
E 243 E 244 E 264 E 279 E 315 E 439
K G Q M V R
E G H M V R
E G H M V R
E E Q K A K
E E Q K A K
E G Q K A K
E G Q K A K
E E Q K A K
et al. (1987).ABLE 1
the E
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365PROTECTIVE EFFICACY OF CHIMERIC YF/JE VIRUS IN MICEith an IC LD50 of 1.6 log10 pfu. None of these viruses
ere virulent after IP inoculation of 5.0 log10 pfu demon-
trating, as for SC inoculation, the lack of neuroinvasive-
ess of both viruses for young adult mice (data not
hown). To delineate more precisely the neurovirulence
nd neuroinvasive properties of the viruses, groups of 3-,
-, 7-, and 9-day-old mice were inoculated by the IP route
ith 3.0 log10 pfu 17D vaccine or with 4.0 log10 Chi-
eriVax-JE virus by the IC route. The 17D vaccine was
dministered IP because this virus is lethal for adult mice
hen inoculated by the IC route (as described above)
nd thus would have killed suckling mice by this route. A
ontrol group received a sham IC inoculation with diluent
EMEM containing 10% FBS). Mice were followed for
igns of illness and death for 21 days.
YF-Vax was neuroinvasive and killed 100% of mice
noculated IP at age 3 or 5 days. Age-specific resistance
o neuroinvasion developed ;7 days of age (Table 3).
ChimeriVax-JE was neurovirulent after IC inoculation in
ice 3 and 5 days of age. Resistance to neurovirulence
ppeared around age 7 days, at which point the mortality
atio was 40%. Mortality was higher in 9-day-old mice,
uggesting that full expression of age-specific resis-
ance occurs at a higher age than tested. It is also
ossible that mice in the 9-day age group died of a
onspecific cause. In Experiment 3, groups of 8-day-old
ice were inoculated IC with YF 17D (Arilvax) at doses
arying between 3.4 log10 pfu and 1.4 log10 pfu or with
himeriVax-JE virus at a fixed dose of 3.5 log10 pfu. All
ice receiving $2.4 log10 pfu of YF 17D virus died of
ncephalitis. Eight of 12 mice (66%) receiving 1.4 log10 pfu
T
Summary of Nucleotide Differences in
Gene NTa ChimeriVaxb 17D2
S2A 4025 A
S3 5362 C
5461 C
5641 G
S4A 6529 C
6625 A
6758 G
S4B 7319 A
7497 T
8212 T
8581 C
9605 G
10722 G
Note. Bold nucleotides are those that differ between ChimeriVax-JE a
hanges result in amino acid substitution in ChimeriVax-JE.
a Nucleotide numbers (NT) are from 59 terminus of the genome. If a
s shown from left to right (e.g., from ChimeriVax to 17D204WHO).
b ChimeriVax is the chimeric YF/JE research virus which is 2 Vero a
c Rice et al. (1985).
d Dupuy et al. (1989).
e Duarte dos Santos et al. (1995).f YF 17D vaccine died with an average survival time
AST) of 10.5 days. In contrast only 4 of 12 mice (33%) that
eceived 3.5 log10 pfu of ChimeriVax-JE virus died, with
n AST of 9.7 days. These studies demonstrated that
himeriVax-JE virus is significantly less neurovirulent
han commercial YF 17D vaccine viruses.
eplication of ChimeriVax-JE in mouse brain
Because the chimeric virus did not cause clinical
igns of illness in young adult mice after IC inoculation,
t was interesting to determine whether the virus repli-
ates in brain tissues. As shown in Fig. 1, the virus grew
o a peak titer of ;6 log10 pfu/g of brain on Day 6 p.i.
iters decreased over the subsequent course of obser-
ation (through Day 12; Fig. 1). We did not determine the
ime to complete viral clearance from the brains in this
xperiment. Because brains of three mice were pooled
o determine brain virus titers, differences among indi-
idual mice were not assessed by this experiment.
enetic stability of attenuating mutations during
n vitro and in vivo passage
In vitro passage. To ascertain that there would be no
enetic changes with passages in cell culture during man-
facturing of vaccine and to identify if there are ‘‘hot spots’’
n the vaccine virus genome where mutations could be
elected, three experiments were carried out. In Experi-
ents 1 and 2, ChimeriVax-JE virus was passed 18 times in
ero cells at a m.o.i. of ;0.1. In Experiment 3, ChimeriVax-JE
irus was passed 10 times in FRhL cells. At selected pas-
Genes of YF 17D Vaccine Substrains
c 17D204Fd 17D204WHOe AA
G G MV
C T
T T
A G
T T
A C
A A VI
A A KE
T C LS
C C
A A
A A DN
A G
lished sequence for 17D204ATCC. Shaded areas are where nucleotide
ide change results in an amino acid substitution, the amino acid (AA)
RhL passages post transfection.ABLE 2
the NS
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366 GUIRAKHOO ET AL.age levels, duplicate samples of viral genomic RNA were
xtracted, reverse-transcribed, amplified by PCR, and the
rME regions or the complete genome sequenced in par-
llel as described under Materials and Methods. Neuro-
irulence tests were performed in 3- to 4-week-old ICR
ice by IC inoculation of 0.03 ml of undiluted and serial
enfold dilutions of cell culture fluids harvested at various
assages. The FRhL-passaged viruses were also tested for
eurovirulence in 8-day-old mice.
In Experiment 1, none of the SA14–14-2 mutations
utatively involved in attenuation underwent reversion
uring passage. A single mutation (CAC to CGC) was
ound at P10 and P18 in the E gene at codon 394
numbering from the amino terminus of the E protein),
T
Neurovirulence and Neuroinvasiveness of Yellow Fever
Experiment Virus
Dose
(log10 pfu)
1 ChimeriVax-JE 4.5
4.0
3.0
2.0
1.0
5.0
4.0
3.0
2.0
1.0
YF 17Dc 4.2
3.9
3.4
2.4
1.4
4.7
4.4
3.4
2.4
1.4
2 ChimeriVax-JE 4.0
YF 17Dc 3.0
3 ChimeriVax-JE 3.5
YF 17De 3.4
2.4
1.4
a Ages of mice are in parentheses.
b Mortality rate expressed as a percentage is in parentheses.
c YF-Vax, Pasteur-Merieux Connaught.
d Higher age-specific mortality in 9-day than in 7-day mice is atypica
e Arilvax, Medeva Pharma Ltd.eading to amino acid change from H to R. A mixture of
(consensus) and G (mutant) was observed at this
osition at both passages. In Experiment 2, the SA14–
4-2 mutations were also preserved across 18 pas-
ages in Vero cells. A single mutation occurred in the
gene at P18 but at a different site than that observed
n Experiment 1, indicating that there were no ‘‘hot
pots’’ for selective mutagenesis in the viral genome.
his mutation occurred at E-271 (GTG to ATG), result-
ng in an amino acid substitution from V to M. This
utation could not be found in P14 or in earlier pas-
ages. Again the mutated nucleotide appeared heter-
geneous (mixture of consensus and mutant codon).
he selected mutations were found in duplicate sam-
nd ChimeriVax-JE Viruses in Adults and Suckling Mice
straina Route
No. dead/No.
inoculatedb
(mortality rate)
AST
(days)
R IC 0/5 (0)
wk) 0/5 (0)
0/5 (0)
0/5 (0)
0/5 (0)
SC 0/5 (0)
0/5 (0)
0/5 (0)
0/5 (0)
0/5 (0)
IC 5/5 (100) 8.8
5/5 (100) 9.4
5/5 (100) 9.4
3/5 (60) 10.0
3/5 (60) 11.0
SC 0/5 (0)
0/5 (0)
0/5 (0)
0/5 (0)
0/5 (0)
(ICR) IC
ays) 9/9 (100) 10.2
ays) 11/11 (100) 10.9
ays) 4/10 (40) 11.5
ays) 11/13 (85)d 11.0
(ICR) IP
ays) 9/9 (100) 9.0
ays) 11/11 (100) 11.0
ays) 2/10 (20) 10.5
ays) 1/10 (10) 12.0
R IC 4/12 (33) 9.7
ays)
R IC 15/15 (100) 7.4
ays) 14/14 (100) 8.6
8/12 (66.6) 10.5
may reflect nonspecific cause of death in the 9-day group.ABLE 3
17D a
Mouse
IC
(4
CD-1
(3 d
(5 d
(7 d
(9 d
CD-1
(3 d
(5 d
(7 d
(9 d
IC
(8 d
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(8 d
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367PROTECTIVE EFFICACY OF CHIMERIC YF/JE VIRUS IN MICEles from Experiments 1 and 2, arguing against any
T–PCR artifacts obscuring the data. The full genomic
equence was determined for P18 in Experiment 1.
here were no mutations in the yellow fever portion (C
r NS regions) of the virus when compared with that of
he ChimeriVax-JE virus. Sequencing of the P5 virus
roduced in FRhL cells revealed no changes in the
rME regions, but a nucleotide transversion (from ACA
o AAA) was found in P10 that resulted in amino acid
ubstitution from T to K at position 281 in the E protein.
his change was found in both duplicate samples.
Neurovirulence phenotypes of P1, P5, and P10 virus
assed in FRhL cells and P1, P10, and P18 virus passed
n Vero cells were determined in 3-to 4-week-old outbred
ice by IC inoculation of various doses (from 3 to 7 log10
fu). No mice died, indicating that the attenuation phe-
otype was maintained across 18 passages in Vero cells
Experiments 1 and 2) and across 10 passages in FRhL
ells (data not shown). The P2 and P5 viruses produced
n the FRhL MCB were also compared with Chi-
eriVax-JE by IC inoculation (3.5 log10 pfu) into groups of
-day-old mice. No significant change in mortality rates
r AST were observed in mice inoculated with these
assages. One of 13, 4 of 13, and 4 of 12 mice died from
2, P5, and ChimeriVax-JE, respectively.
In vivo passage. The stability of the ChimeriVax-JE
irus during in vivo passage was examined. Because
f the known ability of flaviviruses to become neuro-
dapted on brain–brain passage in mice (Collier et al.,
959), we considered this study to be a relevant test of
enetic stability of the attenuating mutations of the
himeriVax-JE virus. It was found that the titer of virus
n brains harvested 6 days after IC inoculation was
table across six passages (6 log10 pfu/g) with no
vidence for increasing titer (neuroadaptation). The
ttenuation phenotype was maintained across 6 pas-
FIG. 1. Growth kinetics of ChimeriVax-JE virus in mouse brain. Ten
roups (n 5 4) of 3- to 4-week-old ICR mice were inoculated by the IC
oute with 3.0 log10 pfu of ChimeriVax-JE virus. At selected intervals
Day 1–12), brains of four mice were harvested, pooled and homoge-
ized (20% W/V) and virus titers were determined by plaque assay in
ero cells.ages. All mice (3- to 4-week old) inoculated IC with
.5 log10 pfu of brain homogenates from P1 to P6
eroconverted, with neutralizing (N) titers of .1:80 on
ay 21. Mice (3- to 4-week old) immunized SC with 4.5
og10 pfu of virus at each passage level also developed
anti-JE antibody responses. There was no difference
n geometric mean N antibody titers across the test
roups. As a more sensitive test of neurovirulence, the
6 virus was tested by IC inoculation of 8-day-old
ice. At this age, mice begin to show age-related
esistance to IC inoculation of YF 17D and Chi-
eriVax-JE viruses. There was no increase in neuro-
irulence for 8-day-old mice when mouse-brain P6
irus was compared with ChimeriVax-JE. Four of 12
ice inoculated with 3.5 log10 pfu of P6 or Chi-
eriVax-JE virus died (data not shown). These results
ndicated a high level of genetic stability of the virus in
resence of selection for neuroadaptation. Viral RNA
equenced at P6 level revealed no mutation in the E
ene. Thus none of the attenuating loci of the E gene
as altered during sequential mouse brain passage. A
ingle mutation was observed in the prME sequence,
t nucleotide 766 (A to C transversion), causing an
mino acid change from Q to P at residue 97. This
utation was observed in both duplicate samples and
equencing of the negative control gave no sequence
ata as expected. A low-intensity signal (A) was ob-
erved in the sequence data, suggesting that a small
ercentage of the viral population is the original Chi-
eriVax-JE virus at this nucleotide position.
TABLE 4
Geometric Mean Neutralizing Antibody Titers (GMT) 3 and 8 Weeks
fter Immunization of Outbred Mice Inoculated with Graded Doses of
accines by the SC Route
Vaccine
Dose
(log10 PFU)
Neutralizing antibody titera (GMT)
vs.
JE YF 17D
3 weeks 8 weeks 3 weeks 8 weeks
himeriVax-JE 5.0 $121b $970
4.0 $35 $70
3.0 $8 $9
2.0 3 $2
1.0 2 1c
F-Vax 4.7 1 6
4.4 $30 $92
3.4 $4 $14
2.4 1 $40
1.4 1 $40
a Reciprocal of the highest dilution of serum that resulted in 50%
eduction of plaque numbers.
b The end point titer was not achieved with at least one animal.
c Titer less than the lowest serum dilution (1:10) tested.g
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368 GUIRAKHOO ET AL.mmunogenicity and protection against challenge
n mice
Immunogenicity of ChimeriVax-JE and YF-Vax in
ice. The immunogenicity of the ChimeriVax-JE re-
earch virus was compared with YF-Vax in outbred
ice. Groups of five 4-week-old ICR mice were inoc-
lated SC with graded doses of the viruses (Table 4).
nimals were bled 3 and 8 weeks later, and 50%
laque-reduction neutralizing titers were determined
gainst the homologous virus. The highest neutraliz-
ng antibody titers were observed 8 weeks after im-
unization in mice receiving 5 log10 pfu of Chi-
eriVax-JE virus [geometric mean (GMT) N antibody
iter $970]. Interestingly, the highest concentration of
he YF 17D vaccine did not induce significant titers of
eutralizing antibodies 3 or 8 weeks postimmuniza-
ion, but antibodies were elicited at lower doses. Neu-
ralizing antibody titers in mice that received lower
oses of YF-Vax was slightly higher (after 8 weeks)
ompared with similar groups that received the Chi-
eriVax-JE virus. It is likely that the chimeric virus is
omewhat less infectious for mice than YF 17D virus.
owever, when inoculated at an infective dose, the
himera appears to elicits a higher immune response.
his may be due to higher replication in or altered
ropism for host tissues.
Protection against challenge with virulent JE virus.
himeriVax-JE virus was evaluated for protection in
57/BL6 mice. We selected these mice because they
re susceptible to lethal infection after IP inoculation
ith certain wild-type JE viruses. Mice were immu-
ized by the SC route with graded doses of viruses
nd observed for 21 days, at which time surviving
nimals were bled for determination of anti-JE neutral-
zing antibody titers. On Day 28 they were challenged
y IP inoculation of 158 LD50 (2000 PFU) of JE virus
IC-37). Protection is expressed as the proportion of
ice surviving 21 days after challenge. ChimeriVax-JE
irus was effective at protecting mice immunized with
103 pfu. There was only a single fatality in the group
iven 104 pfu of the ChimeriVax-JE virus (Table 5); the
0% protective dose of the chimeric virus was 2.3 log10
fu. Animals that received three doses of JE-Vax were
olidly protected against challenge, but mice given a
ingle dose of the SA14–14-2 vaccine were poorly
rotected. As expected, yellow fever 17D virus did not
ross-protect against JE challenge. Wild-type Na-
ayama virus was lethal for a proportion of animals in
dose-dependent fashion; survivors were poorly pro-
ected against challenge indicating that the lethal
ose was close to the infecting dose for this virus. The
F/JE Nakayama chimeric virus was also neuroinva-
ive in C57/BL6 mice, and all mice given 5 log10 pfu of
he chimera died after SC inoculation.DISCUSSION
In this paper, we describe the neurovirulence pheno-
ype, immunogenicity, and genetic stability of a recombi-
ant chimeric YF/JE virus proposed as a live, attenuated
accine candidate.
Similar to results of growth kinetics in LLC-MK2 and
6/36 cells (Chambers et al., 1999), the ChimeriVax-JE
eplicated efficiently in Vero cells. Because at present
one of these cell lines is approved as a substrate for
ive, parentally administered viral vaccines, we explored
ther approved cell lines (human- and monkey-derived
iploid cells) such as MRC-5 and FRhL cells. The chi-
era grew to similar levels (6 log10 pfu/ml) with no sign
f CPE in both cell lines. The titers declined upon further
ncubation, particularly in MRC-5 cells. The reason for a
ow yield at high m.o.i. in FRhL cells or loss of infectious
irus from Day 4 to 8 is not clear but may reflect gener-
tion of defective interfering particles or interferon. No
ncrease in virus yield in FRhL cells was achieved by
ddition of 70 mM MgSO4 and 32°C temperature (Hal-
tead et al., 1984) or interferon inhibitors such as 2-amino-
TABLE 5
Protection of C57/BL6 Mice by a Single SC Inoculum of Graded
oses of Live Virus Vaccines against IP Challenge with Virulent JE
irus (IC-37)
Virus
Number of survivors/no. challengeda by vaccine
dose (log10 pfu)
None 101 102 103 104 105 Other
himeriVax-JE 1/8 2/8 7/7 7/8 7/7
(12.5) (25) (100) (87.5) (100)
F 17D (iv5.2) NTb 0/8 1/8 1/8 1/8
(0) (12.5) (12.5) (12.5)
F-Vax NT 3/8 1/8 1/8 2/8
(37) (12.5) (12.5) (25)
E Nakayamac NT 2/7 1/6 1/3 1/4
(29) (17) (33) (25)
E SA14-14-2 NT 1/8 1/8 0/8 3/8
(12.5) (12.5) (0) (37.5)
F/JE (Nakayama)c NT 3/3 5/5 3/3 e
(100) (100) (100)
E-Vaxd 7/8
(87)
ontrol 1/8
challenged (12.5)
8/8
unchallenged (100)
Note. Percentage of survivors are given in parentheses.
a Animals were challenged on Day 28 postimmunization with 158
D50 of virulent JE virus (IC-37).
b Not tested.
c Some mice died as a result of inoculation of the wild-type virus at
igh dose, thus fewer mice remained for challenge.
d Three doses (100 mL 1:300 dil. on Day 0, 7 and 100 mL 1:5 dil. on
ay 20).
e No mice survived initial inoculation at this dose.
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369PROTECTIVE EFFICACY OF CHIMERIC YF/JE VIRUS IN MICEurine and indomethacin (Sekellic and Marcus, 1985;
arcus and Sekellic, 1988; unpublished data).
The neurovirulence phenotype of the chimeric virus in
- to 4-week-old mice was compared with that of com-
ercial YF 17D vaccines. All mice inoculated by the IC
oute with YF-Vax died within 7–8 days. In contrast all
ice inoculated with ChimeriVax-JE virus survived with-
ut signs of illness. None of the mice inoculated with
F-Vax or the ChimeriVax-JE virus by the peripheral (SC
r IP) routes showed signs of illness or death. Thus as
reviously reported (Fitzgeorge and Bradish, 1980), YF
7D virus was not neuroinvasive in weaned mice. Be-
ause the chimeric virus is not neurovirulent, it cannot be
etermined from these data whether it entered the cen-
ral nervous system. We showed that the chimeric virus
id replicate in mouse brain after IC inoculation, and
eached a peak titer of 6 log10 pfu/g of brain on Day 6 p.i.
he virus titers in the brain gradually dropped to almost
ndetectable levels by Day 12. Similar results were re-
orted with another attenuated recombinant JE virus,
C-47 (Sumiyoshi et al., 1995). The IC-47 virus peaked at
log10 pfu/g on Day 6 and was cleared from the brain by
ay 14, whereas a virus (IC-37) that differed from IC-47
y a single amino acid substitution (K3 E, position 138
n the E gene) grew to .8 log10pfu/g of brain and killed
ll mice by Day 5.
Because no mortality was observed in 3- to 4-week-old
ice at doses of #6 log10 pfu, we inoculated infant mice
3- to 9-days old) by the IC route with ChimeriVax-JE virus
nd with YF 17D vaccine by the IP or IC route. Mice
ecame resistant to ChimeriVax-JE virus ;7 days of age
t which point the mortality ratio was 40%. In another
xperiment, groups of 8-day-old mice were inoculated IC
ith a fixed dose of ChimeriVax-JE or graded doses of YF
7D vaccine. Only 33% of mice inoculated with 3.5 log10
fu of ChimeriVax-JE died, whereas 100% mice inocu-
ated with 3.4 or 2.4 log10 pfu of YF 17D died. Thus the
eurovirulence in infant mice is a sensitive marker of the
ttenuation phenotype of the ChimeriVax-JE virus. In
um, the ChimeriVax-JE was less neurovirulent than ei-
her of two commercial YF 17D vaccines in suckling and
eanling mice. Similar results were obtained when
hese viruses were inoculated into monkeys by the IC
outes. Monkeys inoculated with ChimeriVax-JE had min-
mal brain and spinal cord lesion scores, which were
ower than those inoculated with YF 17D vaccine
Monath et al., 1999).
Both wild-type JE Nakayama virus and the YF/JE Na-
ayama chimeric virus were partially neuroinvasive in
57/BL6 mice inoculated SC. This is consistent with
arlier studies in which only 3 of 15 3-week-old C57/BL6
ice died after IP inoculation of the YF/JE Nakayama
himeric virus (Chambers et al., 1999). There are 10
mino acid differences between the envelope protein of
he Chimerivax-JE virus and Nakayama virus. Four of
hese residues (107, 138, 176, and 279) are suspected tolay a critical role in attenuation because (a) they appear
nly in attenuated SA14–14-2 substrains and in the Chi-
eriVax-JE virus; (b) they map within putative functional
omains of the E-protein; (c) attenuated vaccine strains
f JE (SA14–14-2, SA14–5-3, and SA14–2-8) differ from
irulent parent SA14 viruses at four common amino acids
138, 176, 315, and 439) (Ni et al., 1994, 1995); and (d) a
irulence determinant was defined at position 138 by site
irected mutagenesis of a full-length JE infectious clone
Sumiyoshi et al., 1995). In studies to be published else-
here, site-directed mutagenesis has been used to re-
ert attenuated residues (as single revertant or multiple
evertants) to wild-type sequences and evaluate their
irulence phenotype in the mouse model (Arroyo et al.,
npublished data). These experiments are relevant to the
afety of ChimeriVax vaccine technology because they
emonstrate that the attenuation phenotype is not solely
ependent on a single amino acid residue.
In protection studies, the survivors from YF/JE Na-
ayama were fully protected against challenge, whereas
hose surviving JE Nakayama were not protected (Table
). These results indicated that the lethal dose of JE
akayama was equivalent to the inoculated dose. In
ontrast YF/JE Nakayama appeared to be more immuno-
enic because survivors inoculated with low doses were
ully protected. Neutralizing antibody responses in mice
mmunized with ChimeriVax-JE virus showed a dose re-
ponse and good correlation with protection. Responses
ere superior to SA14–14-2, wild-type Nakayama or YF-
ax. Animals that received three doses of the inactivated
accine (JE-Vax) were also solidly protected. In contrast,
hose animals immunized with a single dose of the
A14–14-2 vaccine were partially protected; this may
ndicate the requirement of two doses for full protection
s recommended for this vaccine (Hennessy et al., 1996).
s expected animals immunized with YF-Vax or YF 17D
nfectious clone-derived virus were not protected against
E challenge indicating that protection was due to a
ype-specific response.
Genetic stability is a major concern for production of
ny live attenuated viral vaccine. Because of the quasi-
pecies nature of the RNA viruses, it is believed that
hese viruses are heterogenous in their genome and
utations occurs nonspecifically across the genome. If a
utant gains advantage over the original virus, it will
ominate the viral population. In other cases, mutants
re either nonviable and eliminated or replicated as
oninfectious particles and increase the particle/pfu ra-
io in the virus population. In case of polio virus type 3, it
as shown that propagation of the vaccine in cell culture
esulted in rapid selection of virus with reversion at two
ositions in the genome, one of which was directly as-
ociated with neurovirulence of the virus in monkey
Chumakov et al., 1992). Because of the high mutation
ate of RNA viruses, it was necessary to monitor the
tability of the attenuating sites that reside mainly on the
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370 GUIRAKHOO ET AL.nvelope protein of the ChimeriVax-JE virus. The current
himeriVax-JE vaccine lot is prepared in FRhL cells and
s five passages posttransfection. In practice, the chi-
eric vaccine will never be passed more than five times
n cell cultures, decreasing any chances for reversion. In
hree different experiments using Vero and FRhL cells,
he ChimeriVax-JE virus was passed #18 times and was
valuated for its genome stability and virulence pheno-
ype in mice. Although we found one nucleotide change
ubstitution in higher passages ($10), we were not able
o find any hot spot in the genome where mutations
ould reoccur. None of the determinants required for
ttenuation was affected by passage. The chimeric vi-
uses retained their full attenuated phenotype and all
ice survived IC inoculation of doses of #6 log10 pfu of
ll passages tested. This was also true when the chi-
eric virus was passaged six times in vivo (brain to brain
assage in mice).
Genomic heterogeneity was observed when different
ubstrains of YF 17D virus were compared with the
himeriVax-JE virus within the NS genes, presumably
eflecting differences in passage history and plaque-
urification of YF 17D viruses (Rice et al., 1985; Dupuy et
l., 1989, Post et al., 1992; Duarte dos Santos et al., 1995;
arrett, 1997). ChimeriVax-JE virus differed from the pub-
ished sequence of its parent virus 17D-204 ATCC (Rice
t al., 1985) at six nucleotide positions, two of which
esulted in amino acid substitutions within the NS2A and
S4B genes. The substitution at nucleotide 4025 (NS2A
ene) is unique among 17D strains, whereas the substi-
ution at nucleotide 7319 (NS4B gene) is not unique,
ccurring in two of three 17D substrains examined. It is
emarkable that the sequence of the core and NS genes
f the chimeric virus passaged 18 times in Vero cells was
dentical to the unpassaged ChimeriVax-JE virus. How-
ver this is consistent with studies by Xie et al., (1998)
emonstrating that YF 17D vaccine accumulate muta-
ions at a low frequency in human vaccinees. Thus it is
ikely that the core and NS genes of the YF backbone
ncode determinants that maintain genotype of YF 17D
irus.
In addition to the structural proteins of the JE virus
prME) that contain T cell determinants and are involved
n induction of long-lasting immunity (Aihara et al., 1998,
onishi et al., 1997 and 1998), NS proteins of flaviviruses
re known to be a dominant source of T cell epitopes
Despres et al., 1991; Lobigs et al., 1994; Putnak and
chlesinger, 1990; Monath and Heinz, 1996). Specifically,
he NS1 protein of YF virus has been suggested to
e involved in protection against encephalitis in mice
y FcR-dependent protection of anti-NS1 antibodies
Schlesinger et al., 1993). Because the ChimeriVax-JE
irus contains NS proteins of the YF 17D virus, preimmu-
ization with YF 17D vaccine could interfere with Chi-
eriVax-JE vaccination. Conversely vaccination with Chi-
eriVax-JE virus may interfere with seroconversion to YFaccine. Interference between YF and JE vaccines was
tudied during a period of 1 year in outbred mice. No
vidence for interference was found based on neutraliz-
ng antibody responses in animals immunized with Chi-
eriVax-JE virus or YF-Vax and reimmunized at intervals
f 3, 6, or 12 months with the reciprocal virus (Guirakhoo
t al., unpublished data, 1998). Because of low immuno-
enicity of YF 17D in mice, we are currently investigating
he ‘‘antivector’’ immunity in nonhuman primates, which
re more susceptible to YF virus infection.
In summary, the ChimeriVax-JE virus appears to have
n excellent profile as a live attenuated, single dose
accine candidate against JE.
MATERIALS AND METHODS
ells
Vero cells originally obtained from Dr. Joel Dalrymple
USAMRIID) were received from Dr. Thomas Chambers
St. Louis University). LLC-MK2 (CLL-7.1, passage 12),
etal rhesus lung (DBS-FRhL-2 from Macaca mulata, pas-
age 28), and MRC-5 cells (diploid human embryonal
ung) were purchased from ATCC. Cells were grown in
MEM, 1% L-glutamine, 1% nonessential amino acids,
nd 10% fetal bovine serum (FBS) buffered with sodium
icarbonate. A Master cell bank (MCB) of FRhL cells was
repared at passage 19 under contract at Magenta Corp.
Rockville, MD) using FRhL cells obtained from the FDA
nd ATCC at passage 10.
laque reduction neutralization test
Neutralizing antibody titers were determined as de-
cribed by Monath et al., (1999). Briefly, sera were heat
nactivated, serially diluted, and mixed with an equal
olume of virus suspension. The mixtures were incu-
ated at 4°C overnight and added to the Vero cell mono-
ayers. After 1.5-h incubation at 37°C, the first agarose
verlay was added and plates were returned to the
ncubator. Plaques were visualized by addition of a sec-
nd overlay on Day 4, and 50% neutralizing titers (the
ighest dilution of the serum sample reducing the num-
er of plaques by 50%) were calculated.
roduction and amplification of chimeric YF/JE virus
Construction of chimeric YF/JE virus has been de-
cribed in detail elsewhere (Chambers et al., 1999).
riefly, full-length cDNA of the chimeric virus was assem-
led by ligation of restriction fragments of core and NS
enes of the YF 17D vaccine strain and prME genes of
he JE SA14–14-2 vaccine strain propagated in YF/JE
lasmids. Chimeric RNA was transcribed using the SP6
romoter and was used to transfect Vero cells in pres-
nce of Lipofectin (Gibco/BRL). Virus was harvested
Vero1), and amplified to produce a Vero2 seed stock.
his stock was passaged once in FRhL cells. This work
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371PROTECTIVE EFFICACY OF CHIMERIC YF/JE VIRUS IN MICEas performed by Dr. Dennis Trent, Center for Biological
valuation, US Food and Drug Administration, Bethesda
D. FRhL cells were inoculated with Vero2 virus at m.o.i.
f 1.0. Virus was harvested 78 h later, made into aliquots,
nd frozen at 270°C. Virus titers were determined in
ero, LLC-MK2, and CV1 cells using standard plaque
ssays and found to be 6.3, 6.2, and 5.2 log10 pfu/ml in
he respective cell lines. This virus is referred to as
himeriVax-JE in this paper. In addition to ChimeriVax-JE,
chimeric YF/JE Nakayama virus (in which prME genes
f SA14–14-2 have been replaced with wild-type Na-
ayama virus) was included in protection studies. All
ecombinant DNA work was approved by institutional
iosafety committee before initiation.
ther viruses
Virulent JE virus (IC-37) was derived from a full-length
nfectious clone of the JE virus strain JaOArS982, as
escribed by Sumiyoshi et al. (1995). This virus was
ropagated in Vero cells to make a seed stock. IC-37-
erived virus was found to be the most lethal virus for
everal strains of mice having an intraperitoneal (IP)
fu/LD50 of 12.6 and therefore was used as challenge
irus. The JE Nakayama strain was obtained from CDC,
t. Collins, CO, and amplified once in Vero and once in
eLa cells. The JE SA14–14-2 virus was one SW13 cell
assage of freeze-derived vaccine obtained from Dr. Yu
n China. Commercial YF 17D vaccine (YF-Vax) and JE
ouse-brain-derived vaccine (JE-Vax) were purchased
rom Pasteur-Merieux-Connaught Laboratories, Swiftwa-
er, PA. In some experiments, a second YF 17D vaccine
Arilvax, Medeva Pharma Ltd, Speke, UK) was used in-
tead of YF-Vax. All current commercial 17D vaccines are
roduced at passage level between 233 and 239 from a
HO primary seed (designated 17D-213–77) free from
vian leukosis virus. YF5.2iv, a molecular clone of the YF
7D strain (Rice et al., 1989), was passaged twice in Vero
ells after transfection.
ouse experiments
For studies of neurovirulence, mice of different ages
ere inoculated by the intracerebral (IC) route. Three- to
-week-old ICR mice were purchased form Taconic
arms, Inc. (Germantown, NY). Suckling mice (3- to
-days old) were born on site from pregnant ICR female
ice purchased from Taconic or from pregnant female
D-1 (ICR) mice purchased from Charles River Labora-
ories (Wilmington, MA). For studies of immunogenicity
nd protection against challenge, we used C57/BL6 mice
urchased from Harlan Sprague–Dawley (Indianapolis,
N). C57/BL6 mice were selected because they are sus-
eptible to lethal infection after IP inoculation with cer-
ain virulent JE viruses, whereas outbred mice are not
niformly susceptible. C57/BL6 mice were immunized
ubcutaneously (SC) with graded doses of virus in 100 mlnd challenged 28 days later with 2000 pfu (equivalent to
58 LD50) of IC-37 virus by the IP route. Animals were
bserved for 21 days and deaths were recorded. Mori-
und animals were euthanized under anesthesia.
For in vivo genetic stability studies, two groups of 3- to
-week-old-ICR mice were inoculated with 3.0 log10 pfu
f ChimeriVax-JE by the IC route. Brains were harvested
n Day 6 (previously determined to contain maximum
rain virus) from the first group and passed to two new
roups of mice by IC inoculation while mice in the sec-
nd group were observed for 21 days to determine viru-
ence phenotype. This cycle was repeated 6 times (P6).
he P6 virus was titrated by plaque assay, and the
ucleotide sequence was determined across the prME
egion and evaluated for its immunogenicity and neuro-
irulence in mice. All animal work was carried out under
rotocols approved by the institutional animal care and
se committee.
NA sequencing
Total RNA was extracted from duplicate samples of a
0% (W/V) homogenate of mouse brain or cell culture
upernatants using a Qiagen Viral RNA extraction kit
Qiagen, Valencia, CA). Reverse-transcription (RT) was
erformed with Superscript II reverse-transcriptase (Life
echnologies), followed by RNaseH treatment (Promega)
nd long-PCR (XL PCR, Perkin–Elmer/ABI, Foster City,
A). RT, PCR, and sequencing primers were designed
sing YF 17D strain sequence (GenBank Accession No.
02749) and JE SA14–14-2 strain sequence (GenBank
ccession No. D90195) as references. For whole ge-
ome sequencing RT primers used were: yf10.8(2)
9-AGTGGTTTTGTGTTTGTC and yf5.4(2) 59-AGTTAACA-
CCCTAGTTG; and PCR primer pairs: yf18(1) 59-AGTA-
ATCCTGTGTGCTA and yf7.4(2) 59-AAGAAGGAGATATA-
AGC; or yf7.2(1) 59-CAGTGATGCCTCTGCTCT and yf10.8(2).
or prME region, sequencing RT primer used was
f2.6(2) 59-AAGAGGCTTTCACTATTGATG; PCR primer
air was yf0.2(1) 59-ATGGTACGACGAGGAGTTCGC and
f2482(2) 59-ATCTCCGCACTTGAGCTC. PCR products
ere gel-purified (Qiaquick gel-extraction kit from Qia-
en) and sequenced using Dye-Terminator dRhodamine
equencing reaction mix (Perkin–Elmer/ABI). Sequenc-
ng reactions were analyzed on a model 310 Genetic
nalyzer (Perkin–Elmer/ABI) and DNA sequences were
valuated using Sequencher 3.0 (GeneCodes) software.
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